234 related articles for article (PubMed ID: 32606608)
21. Evaluation of the antileukemic effects of neurokinin-1 receptor antagonists, aprepitant, and L-733,060, in chronic and acute myeloid leukemic cells.
Dikmen M; Gökhaner G; Cantürk Z
Anticancer Drugs; 2019 Aug; 30(7):e0769. PubMed ID: 31306152
[TBL] [Abstract][Full Text] [Related]
22. A bioluminescent microbial biosensor for in vitro pretreatment assessment of cytarabine efficacy in leukemia.
Alloush HM; Anderson E; Martin AD; Ruddock MW; Angell JE; Hill PJ; Mehta P; Smith MA; Smith JG; Salisbury VC
Clin Chem; 2010 Dec; 56(12):1862-70. PubMed ID: 20921267
[TBL] [Abstract][Full Text] [Related]
23. Expression of TFRC helps to improve the antineoplastic effect of Ara-C on AML cells through a targeted delivery carrier.
Wu X; Jiao Z; Zhang J; Li F; Li Y
J Nanobiotechnology; 2023 Apr; 21(1):126. PubMed ID: 37041636
[TBL] [Abstract][Full Text] [Related]
24. Enhancement of the cytotoxic effects of Cytarabine in synergism with Hesperidine and Silibinin in Acute Myeloid Leukemia: An in-vitro approach.
Desai UN; Shah KP; Mirza SH; Panchal DK; Parikh SK; Rawal RM
J Cancer Res Ther; 2015; 11(2):352-7. PubMed ID: 26148599
[TBL] [Abstract][Full Text] [Related]
25. Rapamycin, the mTOR kinase inhibitor, sensitizes acute myeloid leukemia cells, HL-60 cells, to the cytotoxic effect of arabinozide cytarabine.
Janus A; Linke A; Cebula B; Robak T; Smolewski P
Anticancer Drugs; 2009 Sep; 20(8):693-701. PubMed ID: 19584709
[TBL] [Abstract][Full Text] [Related]
26. Curcumin sensitizes response to cytarabine in acute myeloid leukemia by regulating intestinal microbiota.
Liu J; Luo W; Chen Q; Chen X; Zhou G; Sun H
Cancer Chemother Pharmacol; 2022 Feb; 89(2):243-253. PubMed ID: 35066694
[TBL] [Abstract][Full Text] [Related]
27. [Experimental study of cord blood plasma enhancing the anti-leukemia effect of Ara-C].
Zhang X; Chen Y; Wang X
Zhonghua Xue Ye Xue Za Zhi; 1999 May; 20(5):229-31. PubMed ID: 11601208
[TBL] [Abstract][Full Text] [Related]
28. Cell cycle perturbations in acute myeloid leukemia samples following in vitro exposures to therapeutic agents.
Banker DE; Groudine M; Willman CL; Norwood T; Appelbaum FR
Leuk Res; 1998 Mar; 22(3):221-39. PubMed ID: 9619914
[TBL] [Abstract][Full Text] [Related]
29. The effects of cytarabine combined with ginsenoside compound K synergistically induce DNA damage in acute myeloid leukemia cells.
Qi W; Yan X; Xu X; Song B; Sun L; Zhao D; Sun L
Biomed Pharmacother; 2020 Dec; 132():110812. PubMed ID: 33059263
[TBL] [Abstract][Full Text] [Related]
30. Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: a Danish national phase III trial. The Danish Society of Hematology Study Group on AML, Denmark.
Hansen OP; Pedersen-Bjergaard J; Ellegaard J; Brincker H; Boesen AM; Christensen BE; Drivsholm A; Hippe E; Jans H; Jensen KB
Leukemia; 1991 Jun; 5(6):510-6. PubMed ID: 2056774
[TBL] [Abstract][Full Text] [Related]
31. Cytosine arabinoside (ara-C) and cis-dichlorodiammineplatinum II (cisplatin) alone and in combination: effects on acute myeloblastic leukemia blast cells in culture and in vivo.
Wang YF; Curtis JE; Lipton J; Minkin S; McCulloch EA
Leukemia; 1991 Jun; 5(6):522-7. PubMed ID: 1711641
[TBL] [Abstract][Full Text] [Related]
32. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia.
Berman E; Heller G; Santorsa J; McKenzie S; Gee T; Kempin S; Gulati S; Andreeff M; Kolitz J; Gabrilove J
Blood; 1991 Apr; 77(8):1666-74. PubMed ID: 2015395
[TBL] [Abstract][Full Text] [Related]
33. Rapid in-vitro testing for chemotherapy sensitivity in leukaemia patients.
Anderson E; Salisbury V
Adv Biochem Eng Biotechnol; 2014; 145():189-214. PubMed ID: 25216956
[TBL] [Abstract][Full Text] [Related]
34. IL-6 promotes chemoresistance via upregulating CD36 mediated fatty acids uptake in acute myeloid leukemia.
Zhang Y; Guo H; Zhang Z; Lu W; Zhu J; Shi J
Exp Cell Res; 2022 Jun; 415(1):113112. PubMed ID: 35346671
[TBL] [Abstract][Full Text] [Related]
35. Octadecyloxyethyl Adefovir Exhibits Potent in vitro and in vivo Cytotoxic Activity and Has Synergistic Effects with Ara-C in Acute Myeloid Leukemia.
Khoury H; He R; Schimmer A; Beadle JR; Hostetler KY; Minden MD
Chemotherapy; 2018; 63(4):225-237. PubMed ID: 30372692
[TBL] [Abstract][Full Text] [Related]
36. HOTAIRM1 knockdown enhances cytarabine-induced cytotoxicity by suppression of glycolysis through the Wnt/β-catenin/PFKP pathway in acute myeloid leukemia cells.
Chen L; Hu N; Wang C; Zhao H
Arch Biochem Biophys; 2020 Feb; 680():108244. PubMed ID: 31904363
[TBL] [Abstract][Full Text] [Related]
37. Duocarmycin SA Reduces Proliferation and Increases Apoptosis in Acute Myeloid Leukemia Cells In Vitro.
Chen WA; Williams TG; So L; Drew N; Fang J; Ochoa P; Nguyen N; Jawhar Y; Otiji J; Duerksen-Hughes PJ; Reeves ME; Casiano CA; Jin H; Dovat S; Yang J; Boyle KE; Francis-Boyle OL
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673926
[TBL] [Abstract][Full Text] [Related]
38. Mechanism of cytosine arabinoside toxicity to the blast cells of acute myeloblastic leukemia: involvement of free radicals.
Hu ZB; Yang GS; Li M; Miyamoto N; Minden MD; McCulloch EA
Leukemia; 1995 May; 9(5):789-98. PubMed ID: 7769841
[TBL] [Abstract][Full Text] [Related]
39. Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults.
Kornblau SM; Gandhi V; Andreeff HM; Beran M; Kantarjian HM; Koller CA; O'Brien S; Plunkett W; Estey E
Leukemia; 1996 Oct; 10(10):1563-9. PubMed ID: 8847890
[TBL] [Abstract][Full Text] [Related]
40. Every-other-day palonosetron plus aprepitant for prevention of emesis following induction chemotherapy for acute myeloid leukemia: A randomized, controlled study from the "Rete Ematologica Pugliese".
Di Renzo N; Melillo L; Porretto F; Dargenio M; Pavone V; Pastore D; Mazza P; Mannina D; Merenda A; Cascavilla N; Greco G; Matera R; Bonizzoni E; Celio L; Musso M
Cancer Med; 2020 Jan; 9(1):170-178. PubMed ID: 31725196
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
